v3.25.2
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 14, 2024
Apr. 12, 2024
$ / shares
shares
Apr. 11, 2024
USD ($)
$ / shares
shares
Jun. 14, 2014
Jun. 30, 2025
USD ($)
$ / shares
Dec. 31, 2024
USD ($)
$ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Common stock, par value         $ 0.001 $ 0.001
Reverse stock split, ratio 0.1     0.1    
Preferred stock, par value         $ 0.001 $ 0.001
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]         srt:ChiefExecutiveOfficerMember  
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description         regularly reviews scientific data from clinical and preclinical studies and forecasted expenses for continuing operations.  
Cash, cash equivalents and short-term investments | $         $ 191,600  
Accumulated deficit | $         $ (271,381) $ (231,719)
GT Medical Technologies, Inc. [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Stock issued during period, shares | shares   279,516        
Common stock, par value   $ 0.0001        
Percentage of issued and outstanding capital stock   0.50%        
Oppenheimer & Co [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Stock issued during period, shares | shares     3,535,246      
Stock purchase price per share     $ 14      
Proceeds from issuance of common stock | $     $ 49,500